Pharmaceutical company Gilead Sciences has refused to directly sell its HIV prevention drug to Doctors Without Borders.

By Mariam Sunny March 23 (Reuters) - Gilead Sciences said on Monday it would buy privately held biotech firm Ouro Medicines ...

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company ...

Gilead Sciences extended the expiration of its tender offer to acquire Arcellx. The offer, which was previously scheduled to expire Thursday, will now expire April 24. In February, Gilead agreed to ...

The move came after months of talks in which Doctors Without Borders asked Gilead Sciences for a “limited” supply of ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

Preview this article 1 min A humanitarian group says the company’s supply efforts aren’t meeting the moment. How AI is ...

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new ...

Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs ...

Gilead increased CEO Daniel O’Day's compensation by 20% in 2025 to $28.4 million, putting him among the highest-paid chief ...